KRAS and pancreatic ductal adenocarcinoma: Additionally, 2/10 of EL-KRAS/PEDF−/− mice developed pancreatic ductal adenocarcinoma with distant liver metastases (Figure 3b), compared to 0/10 EL-KRAS control mice.